国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
4期
633-636
,共4页
青光眼%药物疗法%视神经保护%视网膜神经节细胞
青光眼%藥物療法%視神經保護%視網膜神經節細胞
청광안%약물요법%시신경보호%시망막신경절세포
glaucoma%drug therapy%neuroprotection%retinal ganglion cell
青光眼是以视网膜神经节细胞及视神经轴突的丢失为特征的神经变性疾病。现有证据表明眼压升高仅仅是青光眼的许多危险因素之一,很多患者虽然已有效地降低了眼压但疾病仍然处于进展中。本文对青光眼视神经保护相关的药理学方法、基因治疗、免疫调节代谢物和接种疫苗、干细胞疗法和生物能疗法,以及目前相关的药物疗法进行综述,展望青光眼视神经保护治疗新前景。
青光眼是以視網膜神經節細胞及視神經軸突的丟失為特徵的神經變性疾病。現有證據錶明眼壓升高僅僅是青光眼的許多危險因素之一,很多患者雖然已有效地降低瞭眼壓但疾病仍然處于進展中。本文對青光眼視神經保護相關的藥理學方法、基因治療、免疫調節代謝物和接種疫苗、榦細胞療法和生物能療法,以及目前相關的藥物療法進行綜述,展望青光眼視神經保護治療新前景。
청광안시이시망막신경절세포급시신경축돌적주실위특정적신경변성질병。현유증거표명안압승고부부시청광안적허다위험인소지일,흔다환자수연이유효지강저료안압단질병잉연처우진전중。본문대청광안시신경보호상관적약이학방법、기인치료、면역조절대사물화접충역묘、간세포요법화생물능요법,이급목전상관적약물요법진행종술,전망청광안시신경보호치료신전경。
Glaucoma is aneurodegenerative disease characterized by loss of retinal ganglion cells and their axons.Recent evidence suggests that intraocular pressure ( IOP) is only one of the risk factors for glaucoma, and the disease progression continues in many patients, despite the IOP has been lowered effectively.This review summarized the latest advances in glaucoma neuroprotection, such as the pharmacological approaches, gene therapy, immunomodulators and vaccination, stem cell therapy, bioenergetics, and provided new outlook of neuroprotection therapy for glaucoma.